Advancing BNCT

An Emerging Precision Medicine Modality to Treat Solid Tumors

about BNCT

BNCT holds the potential to overcome poor survival rates for patients with a variety of cancers

Boron neutron capture therapy (BNCT) was initially conceived in the early 20th century. Due to recent advances in boron medicinal chemistry and targeted delivery of safe neutrons, the technology has shown great promise for treating patients with solid tumors.


Boron medicines are administered intravenously


Boron medicines preferentially accumulate in tumor cells


Tumor is precisely irradiated with safe, low-energy neutrons


Interaction of safe neutrons with boron medicines releases alpha particles that selectively destroy the tumor


Despite improvements in cancer outcomes over recent decades, there is still a high unmet clinical need for effective treatments. Cytotoxic drugs, traditional radiation therapies and immunotherapies are limited in their effectiveness and can result in adverse side effects. Boron neutron capture therapy is a precision medicine approach to destroy cancerous cells while leaving healthy cells unharmed.

Highly precise

Together with advanced neutron delivery technologies, BNCT medicines have the ability to precisely target tumors

Potentially fewer treatments

Studies have shown that BNCT has the potential to destroy tumors in fewer treatments compared to other modalities

Low intrinsic toxicity

Boron medicines are designed to be non-toxic and are only activated by safe, low-energy neutrons at the tumor

A potentially safe, efficacious and convenient treatment option

Boron neutron capture therapy has been approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for unresectable advanced or recurrent head and neck cancer. Additional clinical research on BNCT is being conducted at 16 BNCT treatment centers worldwide.

The BNCT Ecosystem

To advance BNCT, we are building on generations of innovations in medicinal chemistry, neutron research and biopharmaceutical drug development. Through partnerships with biopharma companies and academic medical centers, we are working to expand access to this promising modality and establish U.S.-based BNCT treatment centers.